Castle Biosciences
Castle Biosciences Q2 Revenues Jump 74 Percent
The firm saw particularly high volume growth for its newer tests, including assays for Barrett's esophagus and IDgenetix, its recently acquired PGx assay.
Palmetto Declines to Cover Molecular Risk Stratification Tests for Cutaneous Squamous Cell Carcinoma
The three other Medicare administrative contractors that participate in the MolDx program aligned their coverage with Palmetto's.
GenomeWeb Top 40 up 2 Percent in March, Following Broader Market
The Dow Jones Industrial Average and Nasdaq also gained 2 percent, while the Nasdaq Biotech Index was essentially flat.
People in the News at Castle Biosciences, InnoSign, EditCo
Recently posted executive and academic appointments, promotions, and departures in omics and molecular diagnostics.
Castle Biosciences Squamous Cell Cancer Test Utility Boosted by New Validation Data, Expert Opinion
Premium
Updated validation data for the DecisionDx-SCC test was published earlier this month, followed by an opinion paper offering consensus guidelines for clinical use.